TOP TEN perturbations for P0CG47 (Homo sapiens)

Organism: Homo sapiens
Gene: P0CG47
Selected probe(set): 200633_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of P0CG47 (200633_at) across 5610 perturbations tested by GENEVESTIGATOR:

OVCAR-8 RIA / OVCAR-8

Relative Expression (log2-ratio):8.395524
Number of Samples:3 / 3
Experimental OVCAR-8 RIA
Human metastatic cancer cell line derived from the ascites fluid from a cisplatin-resistant patient with carcinoma of the ovary. Stably transfected with the cAMP-dependent protein kinase (PKA) regulatory subunit gene for RIα. Parental cell line:: OVCAR-8 Cellosaurus code:
Control OVCAR-8
Human metastatic cancer cell line derived from the ascites fluid from a cisplatin-resistant patient with carcinoma of the ovary. Synonyms:NIH:OVCAR-8; OVCAR8; Ovcar8; OVCAR.8; OVCA8 Cellosaurus code:

OVCAR-8 RIIB / OVCAR-8

Relative Expression (log2-ratio):8.229304
Number of Samples:3 / 3
Experimental OVCAR-8 RIIB
Human metastatic cancer cell line derived from the ascites fluid from a cisplatin-resistant patient with carcinoma of the ovary. Stably transfected with the cAMP-dependent protein kinase (PKA) regulatory subunit gene for RIIβ. Parental cell line:: OVCAR-8 Cellosaurus code:
Control OVCAR-8
Human metastatic cancer cell line derived from the ascites fluid from a cisplatin-resistant patient with carcinoma of the ovary. Synonyms:NIH:OVCAR-8; OVCAR8; Ovcar8; OVCAR.8; OVCA8 Cellosaurus code:

conditioned medium study 1 (HS5) / untreated monocyte (CD14+) sample

Relative Expression (log2-ratio):2.0384617
Number of Samples:2 / 2
Experimental conditioned medium study 1 (HS5)
CD14+ monocytes treated with HS5 conditioned medium (CM) for 48h.
Control untreated monocyte (CD14+) sample
Untreated CD14+ monocytes from two different donors.

conditioned medium study 1 (HS27a) / untreated monocyte (CD14+) sample

Relative Expression (log2-ratio):1.8947525
Number of Samples:2 / 2
Experimental conditioned medium study 1 (HS27a)
CD14+ monocytes treated with HS27a conditioned medium (CM) for 48h.
Control untreated monocyte (CD14+) sample
Untreated CD14+ monocytes from two different donors.

breast cancer study 40 (metastase; ovary) / ovarian tumor study 28 (carcinosarcoma)

Relative Expression (log2-ratio):1.8143005
Number of Samples:44 / 2
Experimental breast cancer study 40 (metastase; ovary)
Metastatic tumor tissue obtained from the ovary of female patients with primary breast cancer.
Control ovarian tumor study 28 (carcinosarcoma)
Primary tumor tissue sample obtained from the ovary of female patients with carcinosarcoma.

ovarian tumor study 25 (serous ovarian cancer epithelium) / normal ovarian surface epithelium cell sample

Relative Expression (log2-ratio):-1.7910442
Number of Samples:12 / 12
Experimental ovarian tumor study 25 (serous ovarian cancer epithelium)
Laser capture micro-dissected serous ovarian cancer epithelium cells derived from female individuals with primary papillary serous adenocarcinoma of the ovary.
Control normal ovarian surface epithelium cell sample
Normal ovarian surface epithelium cell (OSE) samples isolated from female individuals by laser capture micro-dissection (LCM). Indication for removal of healthy ovaries were others than ovary cancer.

ovarian tumor study 13 / normal ovarian surface epithelial cell sample

Relative Expression (log2-ratio):-1.7660999
Number of Samples:18 / 12
Experimental ovarian tumor study 13
Human epithelial tumor cell samples from the ovary of patients with serous adenocarcinoma. Samples were derived by laser capture microdissection (LCM).
Control normal ovarian surface epithelial cell sample
Human epithelial cell samples from histopathological normal and non-cancerous ovary tissue from healthy donors. Samples were derived by cell surface brushing.

fallopian tube tumor study 1 (papillary serous cystadenocarcinoma; metastase) / fallopian tube tumor study 1 (papillary serous cystadenocarcinoma; primary)

Relative Expression (log2-ratio):1.4783764
Number of Samples:6 / 2
Experimental fallopian tube tumor study 1 (papillary serous cystadenocarcinoma; metastase)
Metastatic tumor tissue samples obtained from different anatomical sites (bone, colon, ovary and peritoneum) of female patients with primary papillary serous cystadenocarcinoma of the fallopian tube.
Control fallopian tube tumor study 1 (papillary serous cystadenocarcinoma; primary)
Primary tumor tissue samples obtained from the fallopian tube of female patients with papillary serous cystadenocarcinoma.

glioma study 16 (LN-319) / normal astrocyte sample

Relative Expression (log2-ratio):1.4600086
Number of Samples:2 / 3
Experimental glioma study 16 (LN-319)
Human glioma cell line LN319 was cultured in DMEM supplemented with 10% FCS (fetal calf serum) and antibiotics at 37°C and 5% CO2.
Control normal astrocyte sample
Normal brain astrocytes. Clonetics normal human astrocytes (NHA) from Cambrex (primary-derived cultures) and cultured according to the manufacturer's recommendations.

B-CLL study 11 (rolipram) / rolipram study 4 (normal B-cell; 20uM)

Relative Expression (log2-ratio):-1.4535027
Number of Samples:4 / 4
Experimental B-CLL study 11 (rolipram)
Peripheral blood mononuclear cells (PBMCs) obtained from chronic lymphocytic leukemia (CLL) patients and in vitro treated with rolipram (20 uM, cyclic nucleotide phosphodiesterase (PDE4) inhibitor) for 4 hours. PBMCs’ samples contained 90% CD19+ CD5+ B lineage CLL cells (B-CLL). Inclusion criteria: untreated CLL patients or at least 1 month after chemotherapy. Exclusion criteria: patients with active infections or other serious medical conditions or with white blood cell (WBC) counts of 15,000/l. ATC code:---
Control rolipram study 4 (normal B-cell; 20uM)
MACS purified resting B-cells from healthy donor peripheral blood treated with rolipram (20 uM, cyclic nucleotide phosphodiesterase (PDE4) inhibitor) for 4 hours. ATC code:---